PMID- 17987122
OWN - NLM
STAT- MEDLINE
DCOM- 20080821
LR  - 20220311
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 2
IP  - 11
DP  - 2007 Nov 7
TI  - HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.
PG  - e1138
LID - e1138
AB  - BACKGROUND: Despite a typically good response to first-line combination 
      chemotherapy, the prognosis for patients with advanced ovarian cancer remains 
      poor because of acquired chemoresistance. The use of targeted therapies such as 
      trastuzumab may potentially improve outcomes for patients with ovarian cancer. 
      HER2 overexpression/amplification has been reported in ovarian cancer, but the 
      exact percentage of HER2-positive tumors varies widely in the literature. In this 
      study, HER2 gene status was evaluated in a large, multicentric series of 320 
      patients with advanced ovarian cancer, including 243 patients enrolled in a 
      multicenter prospective clinical trial of paclitaxel/carboplatin-based 
      chemotherapy. METHODOLOGY/PRINCIPAL FINDINGS: The HER2 status of primary tumors 
      and metastases was evaluated by both immunohistochemistry (IHC) and fluorescence 
      in situ hybridization (FISH) analysis of paraffin-embedded tissue on conventional 
      slides. The prognostic impact of HER2 expression was analyzed. HER2 gene was 
      overexpressed and amplified in 6.6% of analyzed tumors. Despite frequent 
      intratumoral heterogeneity, no statistically significant difference was detected 
      between primary tumors and corresponding metastases. CONCLUSIONS/SIGNIFICANCE: 
      Our results show that the decision algorithm usually used in breast cancer (IHC 
      as a screening test, with equivocal results confirmed by FISH) is appropriate in 
      ovarian cancer. In contrast to previous series, HER2-positive status did not 
      influence outcome in the present study, possibly due to the fact that patients in 
      our study received paclitaxel/carboplatin-based chemotherapy. This raises the 
      question of whether HER2 status and paclitaxel sensitively are linked.
FAU - Tuefferd, Marianne
AU  - Tuefferd M
AD  - JE2492, Universite Paris-Sud, IFR69, Villejuif, France.
FAU - Couturier, Jerome
AU  - Couturier J
FAU - Penault-Llorca, Francoise
AU  - Penault-Llorca F
FAU - Vincent-Salomon, Anne
AU  - Vincent-Salomon A
FAU - Broet, Philippe
AU  - Broet P
FAU - Guastalla, Jean-Paul
AU  - Guastalla JP
FAU - Allouache, Djelila
AU  - Allouache D
FAU - Combe, Martin
AU  - Combe M
FAU - Weber, Beatrice
AU  - Weber B
FAU - Pujade-Lauraine, Eric
AU  - Pujade-Lauraine E
FAU - Camilleri-Broet, Sophie
AU  - Camilleri-Broet S
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20071107
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Female
MH  - *Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Ovarian Neoplasms/drug therapy/*genetics/pathology
MH  - Paclitaxel/administration & dosage
MH  - Prognosis
MH  - Prospective Studies
MH  - Survival Analysis
PMC - PMC2042515
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2007/11/08 09:00
MHDA- 2008/08/22 09:00
PMCR- 2007/11/07
CRDT- 2007/11/08 09:00
PHST- 2007/07/09 00:00 [received]
PHST- 2007/10/13 00:00 [accepted]
PHST- 2007/11/08 09:00 [pubmed]
PHST- 2008/08/22 09:00 [medline]
PHST- 2007/11/08 09:00 [entrez]
PHST- 2007/11/07 00:00 [pmc-release]
AID - 07-PONE-RA-01696R3 [pii]
AID - 10.1371/journal.pone.0001138 [doi]
PST - epublish
SO  - PLoS One. 2007 Nov 7;2(11):e1138. doi: 10.1371/journal.pone.0001138.